Weekly Clinigen Group Plc (LON:CLIN) Ratings on Dec 8, 2018

Clinigen Group Plc (LON:CLIN) Corporate Logo

Clinigen Group Plc (LON:CLIN) Ratings Coverage

Total analysts of 4 have positions in Clinigen Group (LON:CLIN) as follows: 4 rated it a “Buy”, 0 with “Sell” and 0 with “Hold”. The positive are 100%. Since July 3, 2018 according to StockzIntelligence Inc Clinigen Group has 14 analyst reports. On Tuesday, October 9 Peel Hunt maintained Clinigen Group Plc (LON:CLIN) rating. Peel Hunt has “Buy” rating and GBX 1300 target. On Wednesday, July 25 Numis Securities maintained the shares of CLIN in report with “Buy” rating. On Thursday, November 1 the firm has “Buy” rating by Peel Hunt given. On Tuesday, July 17 the stock of Clinigen Group Plc (LON:CLIN) has “Buy” rating given by Peel Hunt. On Thursday, September 27 the rating was maintained by Peel Hunt with “Buy”. On Thursday, September 27 UBS maintained Clinigen Group Plc (LON:CLIN) rating. UBS has “Buy” rating and GBX 1160 target. On Monday, October 15 RBC Capital Markets maintained Clinigen Group Plc (LON:CLIN) rating. RBC Capital Markets has “Top Pick” rating and GBX 1470 target. In Wednesday, October 3 report Peel Hunt maintained the stock with “Buy” rating. On Tuesday, September 4 the rating was maintained by Peel Hunt with “Buy”. On Wednesday, August 1 the rating was maintained by Peel Hunt with “Buy”. Listed here are Clinigen Group Plc (LON:CLIN) PTs and latest ratings.

01/11/2018 Broker: Peel Hunt Rating: Buy Old Target: GBX 1300.00 Maintain
15/10/2018 Broker: RBC Capital Markets Rating: Top Pick Old Target: GBX 1360.00 New Target: GBX 1470.00 Unchanged
09/10/2018 Broker: Peel Hunt Rating: Buy Old Target: GBX 1350.00 New Target: GBX 1300.00 Maintain
08/10/2018 Broker: Numis Securities Rating: Buy Old Target: GBX 1275.00 New Target: GBX 1275.00 Maintain
03/10/2018 Broker: Peel Hunt Rating: Buy Old Target: GBX 1350.00 Maintain
27/09/2018 Broker: UBS Rating: Buy Old Target: GBX 1160.00 New Target: GBX 1160.00 Maintain
27/09/2018 Broker: Peel Hunt Rating: Buy Old Target: GBX 1350.00 Maintain
04/09/2018 Broker: Peel Hunt Rating: Buy Old Target: GBX 1350.00 Maintain
01/08/2018 Broker: Peel Hunt Rating: Buy Old Target: GBX 1350.00 Maintain
25/07/2018 Broker: Numis Securities Rating: Buy Old Target: GBX 1208.00 Maintain

CLIN is hitting GBX 816.5 during the last trading session, after increased 0.68%.Currently Clinigen Group Plc is after 0.00% change in last December 8, 2017. CLIN has 243,961 shares volume. The stock underperformed the S&P500 by 15.62%.

Clinigen Group plc operates as a specialty pharmaceutical and services firm in the United Kingdom, Europe, the United States, and internationally.The company has 1.08 billion GBP market cap. The Company’s Clinigen Clinical Trial Services business supplies and manages commercial medical products, including comparator drugs, adjuvant drugs, and rescue therapies for patients in clinical trials, as well as provides value added services.36.29 is the P/E ratio. The companyÂ’s Idis Managed Access business is involved in the consultancy, development, management, and implementation of managed access programs for biotechnology and pharmaceutical companies.

For more Clinigen Group Plc (LON:CLIN) news announced recently go to: Nature.com, Prnewswire.com, Prnewswire.com, Prnewswire.com or Globenewswire.com. The titles are as follows: “Radiofrequency treatment alters cancer cell phenotype | Scientific Reports – Nature.com” announced on July 13, 2015, “FDA Approves SUBLOCADEâ„¢ (Buprenorphine Extended-Release), the First and Only Once-Monthly Injectable Buprenorphine Formulation to Treat Moderate to Severe Opioid Use Disorder – PR Newswire” on November 30, 2017, “SUBLOCADEâ„¢ (Buprenorphine Extended-Release) is Now Available as First and Only Monthly Injectable Buprenorphine in the US to Treat Patients with Moderate to Severe Opioid Use Disorder – PR Newswire” with a publish date: March 01, 2018, “Indivior Announces NDA Acceptance of RBP-7000 Risperidone Monthly Depot – PR Newswire” and the last “G1 Therapeutics Announces Initiation of Phase 1b/2 Clinical Trial of G1T38 in Combination with Tagrisso for EGFR-Mutant Non-Small Cell Lung Cancer – GlobeNewswire” with publication date: April 16, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.